{{Drugbox
| verifiedrevid = 470473303
| IUPAC_name = 4-aminobenzenesulfonamide
| image = Sulfanilamide-skeletal.svg
| image2 = sulfanilamida-3D.png
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|CDI|sulfanilamide}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 63-74-1
| ATC_prefix = J01
| ATC_suffix = EB06
| ATC_supplemental = {{ATC|D06|BA05}} {{ATCvet|J01|EQ06}}
| PubChem = 5333
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00259
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5142
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 21240MF57M
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08543
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 45373
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 21
| NIAID_ChemDB = 019103
<!--Chemical data-->
| C=6 | H=8 | N=2 | O=2 | S=1
| molecular_weight = 172.20 g/mol
| smiles = O=S(=O)(c1ccc(N)cc1)N
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C6H8N2O2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,7H2,(H2,8,9,10)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = FDDDEECHVMSUSB-UHFFFAOYSA-N
| density = 1.08
| melting_point = 165
}}
'''Sulfanilamide''' (also spelled '''sulphanilamide''') is a [[sulfonamide (medicine)|sulfonamide]] [[antibacterial]]. Chemically, it is an [[organic compound]] consisting of an [[aniline]] derivatized with a [[Sulfonamide (chemistry)|sulfonamide]] group.<ref>{{ Ullmann | author = Actor, P.; Chow, A. W.; Dutko, F. J.; McKinlay, M. A. | title = Chemotherapeutics | doi = 10.1002/14356007.a06_173 }}</ref>  Powdered sulfanilamide was used by the Allies in World War II to reduce infection rates and contributed to a dramatic reduction in mortality rates compared to previous wars.<ref>http://www.mtaofnj.org/content/WWII%20Combat%20Medic%20-%20Dave%20Steinert/wwii.htm#The%20Use%20of%20Sulfanilamide%20in%20World%20War%20II</ref><ref>http://www.med-dept.com/sulfa.php</ref>  Modern antibiotics have supplanted sulfanilamide on the battlefield; however, sulfanilamide remains in use for treatment of vaginal yeast infections.<ref>https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5333</ref>

The term "sulfanilamides" is also used to describe a family of molecules containing these functional groups. Examples include: 
* [[Furosemide]], a [[loop diuretic]]
* [[Sulfadiazine]], an [[antibiotic]]
* [[Sulfamethoxazole]], an [[antibiotic]]

==Mechanism of action==
As a sulfonamide antibiotic, sulfanilamide functions by competitively inhibiting (i.e., by acting as a substrate analogue) enzymatic reactions involving [[para-aminobenzoic acid]] (PABA).<ref>Michael Kent, ''Advanced Biology,'' Oxford University Press, 2000, p. 46 {{ISBN|978-0-19-914195-1}}</ref> PABA is needed in enzymatic reactions that produce [[folic acid]], which acts as a coenzyme in the synthesis of [[purine]]s and [[pyrimidine]]s.  Mammals do not synthesize their own folic acid so are unaffected by PABA inhibitors, which selectively kill bacteria.

==History==
Sulfanilamide was first prepared in 1908 by the Austrian chemist Paul Josef Jakob Gelmo (1879–1961)<ref>Biography of Paul Gelmo:  [http://www.encyclopedia.com/doc/1G2-2830901608.html Encyclopedia.com].</ref> as part of his dissertation for a doctoral degree from the Technische Hochsschule of Vienna, Austria.<ref>Paul Gelmo (May 14, 1908) [http://gallica.bnf.fr/ark:/12148/bpt6k90849c/f378.image "Über Sulfamide der p-Amidobenzolsulfonsäure,"] ''Journal für Praktische Chemie'', '''77''' :  369-382.</ref>  It was patented in 1909.<ref>On May 18, 1909, Deutsches Reich Patentschrift number 226,239 for sulfanilamide was awarded to Heinrich Hörlein of the Bayer corporation.</ref>

[[Gerhard Domagk]], who directed the testing of the [[prodrug]] [[Prontosil]] in 1935,<ref>G. Domagk, "Ein Beitrag zur Chemotherapie der bakteriellen Infektionen", ''Deutsche Medizinische Wochenschrift'', '''61''', feb. 15, 1935, p. 250.</ref> and Jacques and Thérèse Tréfouël, who along with Federico Nitti and [[Daniel Bovet]] in the laboratory of [[Ernest Fourneau]] at the [[Pasteur Institute]], determined sulfanilamide as the active form,<ref>J. et T. Tréfouël, F. Nitti and D. Bovet, "Activité du ''p''-aminophénylsulfamide sur l’infection streptococcique expérimentale de la souris et du lapin", ''C. R. Soc. Biol.'', '''120''', nov. 23, 1935, p. 756.</ref> are generally credited with the discovery of sulfanilamide as a chemotherapeutic agent. Domagk was awarded the Nobel Prize for his work.<ref>{{fr}} Daniel Bovet, "Les étapes de la découverte de la sulfamidochrysoïdine dans les laboratoires de recherche de la firme Bayer à Wuppertal-Elberfeld (1927-1932)", in ''Une chimie qui guérit : Histoire de la découverte des sulfamides'', Coll. "Médecine et Société", Payot, Paris, 1988, p. 307.</ref>

A product formulation with [[diethylene glycol]] in the 1930's led to new US regulation for drug testing.

==See also==
* [[Sulfonamide (medicine)]]
* [[Nazi human experimentation#Sulfonamide experiments|Nazi human experimentation — Sulfonamide experiments]]
* [[Elixir sulfanilamide]]

==External links==
* {{MeshName|Sulfanilamides}}

==References==
{{reflist}}

{{Antibiotics and chemotherapeutics for dermatological use}}
{{Sulfonamides and trimethoprim}}

[[Category:Sulfonamide antibiotics]]